Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Headache, Migraine
Conditions
Headache, Migraine
Trial Timeline
Sep 6, 2022 → Nov 1, 2024
NCT ID
NCT05503082About Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]
Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy] is a approved stage product being developed by AbbVie for Headache, Migraine. The current trial status is active. This product is registered under clinical trial identifier NCT05503082. Target conditions include Headache, Migraine.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05503082 | Approved | Active |
Competing Products
20 competing products in Headache, Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 52 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 44 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 52 |
| Galcanezumab 300 mg + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab | Eli Lilly | Phase 3 | 77 |
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| LY2590443 + Placebo injection + Sumatriptan + Placebo capsule | Eli Lilly | Phase 2 | 52 |
| LY2951742 + Placebo | Eli Lilly | Phase 2 | 52 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 2 | 52 |
| Soy Isoflavones | Johnson & Johnson | Pre-clinical | 23 |
| topiramate | Johnson & Johnson | Phase 3 | 77 |
| Placebo + Zolmitriptan + Zolmitriptan + Zolmitriptan | AstraZeneca | Approved | 85 |
| candesartan cilexetil + placebo | AstraZeneca | Phase 2 | 52 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| Propranolol or nadolol + Placebo control + Optimal Acute Therapy | Merck | Approved | 85 |
| AMG 334 | Novartis | Phase 2 | 52 |
| SOM230 + Placebo | Novartis | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |
| Erenumab + Ethynil Estradiol/Norgestimate Oral Contraceptive | Amgen | Phase 1 | 32 |